Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome

BACKGROUND: CYP39A1 is a poorly characterized metabolic enzyme that has been investigated in a few tumors. However, the role of CYP39A1 in hepatocellular carcinoma (HCC) has not yet been clarified. In this study, the expression and clinical significance of CYP39A1 in HCC were explored. METHODS: CYP3...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dan, Yu, Tao, Hu, Junjie, Wu, Jie, Feng, Shi, Xu, Qingxue, Zhu, Hua, Zhang, Xu, Zhang, Yonggang, Zhou, BenHong, Gu, Lijuan, Zeng, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741352/
https://www.ncbi.nlm.nih.gov/pubmed/35003516
http://dx.doi.org/10.1155/2021/5175581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741352/
https://www.ncbi.nlm.nih.gov/pubmed/35003516
http://dx.doi.org/10.1155/2021/5175581

Ejemplares similares